On October 6, 2020 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that it has entered into a license agreement with argenx that grants argenx worldwide non-exclusive rights for Chugai’s antibody engineering technologies (Press release, Chugai, OCT 6, 2020, View Source [SID1234568132]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, argenx will receive the rights to use two Chugai’s antibody engineering technologies (SMART-Ig and ACT-Ig) for their research activities, and option to develop and market therapeutic antibodies applying those technologies. In return for the license, Chugai will receive a fee for technology access. In case argenx creates a candidate antibody and exercises the option, Chugai will receive upfront payment, milestone payment according to the development status, and royalty payment if the compound is launched as an approved antibody drug.